NCT05903937

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes Preconditioned With Percutaneous Hepatic Perfusion With Melphalan in Patients With Melanoma and Liver Metastases

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (estimated)
• Sponsor: Vastra Gotaland Region · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with percutaneous hepatic perfusion in patients with liver metastases (but not restricted to) of malignant melanoma

Conditions

• Uveal Melanoma
• Metastatic Cutaneous Melanoma

Interventions

Type	Name	Description
DRUG	Autologous Tumor Infiltrating Lymphocytes	Administered via hepatic arterial infusion (HAI)
DRUG	Melphalan	Administered via isolated hepatic perfusion
DRUG	Interleukin-2	low-dose, administered s.c.

Timeline

• Start date: 2023-12-31
• Primary completion: 2024-12-31
• Completion: 2029-12-31
• First posted: 2023-06-15
• Last updated: 2023-06-15